Durvalumab plus lenalidomide for relapsed T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL).
- You must have tried at least two prior treatments for your lymphoma, and it must have come back or not responded.
- You need to be in relatively good health, with adequate blood counts, kidney and liver function.
- Women who can have children must use two reliable forms of birth control, and men must use effective contraception, from the start of the study until 90 days after the last dose.
- You cannot have had a stem cell transplant, major surgery within 28 days, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hear when a new Recurrent Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.